购物车
- 全部删除
- 您的购物车当前为空
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1/2.
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1/2.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100 mg | 询价 | 期货 | |
500 mg | 询价 | 期货 |
产品描述 | LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1/2. |
靶点活性 | αvβ3 integrin:0.68 μM |
体外活性 | LXW7 specially binds to αvβ3 integrin (Kd: 76 nM). LXW7 binds strongly to αvβ3-K562 cells, weakly to αvβ5-K562 cells and αIIbβ3-K562 cells, and no binding to K562 cells. LXW7 has great potential as a highly efficient peptide ligand for targeted imaging and drug delivery [1]. LXW7 acts as potent and specific endothelial progenitor cells and endothelial cells targeting ligand [2]. |
体内活性 | LXW7 (100 μg/kg; intravenous injection) significantly lowers infarct volumes and brain water content (BWC) LXW7-treated rats. The LXW7 treatment lowers the expression of pro-inflammatory cytokines[3]. |
别名 | LXW7 TFA |
分子量 | 934.92 |
分子式 | C31H49F3N12O14S2 |
密度 | no data available |
存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容